Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach

George, Tarun K; Nair, Nayana P.; Singh, Awnish Kumar; Kumar, Abhijeet; Roy, Arup Deb; Mohan, Varshini Neethi; Kang, Gagandeep

doi:10.1016/j.vaccine.2023.04.062

Vaccine

2023

DOI: 10.1016/j.vaccine.2023.04.062

|View full text |Cite

Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach

Tarun K George

Nayana P. Nair

Awnish Kumar Singh

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Prioritizing vaccine introduction to China’s National Immunization Program: a multi-criteria decision analysis

Guo,

Zheng,

Chen

et al. 2024

BMC Public Health

View full text Add to dashboard Cite

Background To prioritize the introducing of new vaccines into China’s National Immunization Program (NIP) among 10 candidate vaccines across four classes. Methods We developed a vaccine value framework using Multi-Criteria Decision Analysis (MCDA) to simulate the introduction of new vaccines into NIP, covering 21 criteria encompassing six dimensions: safety, effectiveness, economy, innovation, accessibility, and appropriateness. Two decision scenarios were considered: Scenario One prioritized the four classes of vaccines, while Scenario Two identified specific vaccines within each class. Results In the vaccine value framework, safety received the highest weight, while innovation received the lowest. The Human Papillomavirus (HPV) vaccine was identified as a top priority for inclusion in NIP, followed by Pneumococcal Conjugate Vaccine (PCV), Haemophilus Influenzae Type B (HIB), and Rotavirus (RV) vaccines. The specific types are domestic bivalent HPV vaccine, imported 13-valent PCV vaccine, domestic HIB vaccine, and domestic RV vaccine. The results of the one-way and probabilistic sensitivity analysis demonstrated robustness. Conclusions This study provides a transparent, comprehensive, and quantifiable vaccine value framework to aid decision-making for introducing new vaccines into China’s NIP. According to the MCDA results, HPV should be considered the top vaccine candidate for the NIP. Supplementary Information The online version contains supplementary material available at 10.1186/s12889-024-21013-7.

show abstract

Prioritizing vaccine introduction to China’s National Immunization Program: a multi-criteria decision analysis

Guo,

Zheng,

Chen

et al. 2024

BMC Public Health

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach

Cited by 1 publication

References 33 publications

Prioritizing vaccine introduction to China’s National Immunization Program: a multi-criteria decision analysis

Prioritizing vaccine introduction to China’s National Immunization Program: a multi-criteria decision analysis

Contact Info

Product

Resources

About